RhoA/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats

Prostate cancer (PCa) is the mostcommon non-cutaneous canceramong men in the United States [1]. For some men with non-aggressive PCa, active surveillance could be a viable option. Though survival rates are favorable for localized prostate cancer, treatment-related toxicity become important. The common treatment options for localized PCa include surgery, RT, androgen deprivation therapy (ADT), or a combination of the treatments, and all have associated treatment related toxicities [4 –5]. Approximately 50% of patients undergoing radiation therapy will develop RiED within 3 to 5 years after the completion of RT.

Source: Radiotherapy and Oncology - June 17, 2020 Category: Radiology Authors: Javed Mahmood, Ravina Pandita, Angel Zhang, Shriya Kamlapurkar, Ali Saeed, Minjie Chen, Paul N. Staats, Hem D Shukla, Akbar Anvari, Amit Sawant, Zeljko Vujaskovic Tags: Original Article Source Type: research